Long-term follow-up supports pembrolizumab monotherapy in BCG-unresponsive NMIBC
December 2nd 2022Pembrolizumab monotherapy continued to demonstrate durable complete responses, while rates of upstaging at the time of radical cystectomy were consistent with previous findings in the KEYNOTE-057 trial in patients with BCG-unresponsive NMIBC.
Renal functional decline after radical nephrectomy strongly associated with age
December 2nd 2022“We showed that in the oldest patient cohorts, age became an independent risk factor for development of de novo CKD after surgical intervention in patients who underwent radical nephrectomy," says Mimi Vu Nguyen.
Dr. Galsky explains the biomarker challenge with adjuvant immunotherapy in urothelial cancer
December 2nd 2022“In the adjuvant setting, we have a ‘double biomarker problem.’ Not only don’t we know which drugs work best in which patients, we actually don’t even know which patients need additional systemic treatment because many patients are already cured with surgery,” says Matthew Galsky, MD.
Expert highlights latest developments in penile cancer
December 10th 2021"Although, as urologic oncologists, we all see a few cases in our practices individually, I think, no question, there's a lot of heterogeneity in how penile cancer is managed across the United States," says Philippe E. Spiess, MD, MS.
Dr. Cookson on SUO educational initiatives for 2022
December 9th 2021“We're really moving into not just these annual meetings, but we're going to have some programs throughout the year that will be targeted towards…really important, impactful research that comes out,” says Michael S. Cookson, MD, MMHC, FACS.
Genomic profiling study brings investigators “one step closer” to liquid biopsy in UTUC
December 6th 2021“We’re just getting one step closer to being able to find urine tests that we can use to help risk stratify patients, and then help understand the genetic profiles of other tumors, which might help guide management later on,” says Wesley Yip, MD.